Filing Flows › Halozyme Therapeutics (HALO) › Q2 2026
Halozyme Therapeutics (HALO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Halozyme Therapeutics (HALO) reported revenue of $481M for the second quarter 2026 (Q2 2026), +48% from a year earlier and +28% from the quarter before. Operating margin was 59.8%, net earnings $230M (47.8% of revenue).
Halozyme Therapeutics, Q2 2026: revenue $481M (+48% year over year), operating margin 59.8%, net earnings $230M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $481M | +28% | +48% |
| Operating profit | $288M | +56% | +42% |
| Net earnings | $230M | +53% | +39% |
| Operating cash flow | $241M | +34% | +142% |
| Free cash flow | $237M | +34% | +141% |
What changed
Revenue was $481.0M in Q2 2026, up 48% year over year and up 28% from the previous quarter. Royalties was the largest line at 64% of revenue. Royalties added $102.1M year over year (up 50%), 66% of the total change. Event-based development and regulatory milestones and other fees declined 77%.
Operating profit was $287.7M, a 59.8% margin (down 2.3 points year over year). Of the extra revenue versus Q2 2025, 55% reached operating profit, below the 62% margin then. Total costs grew 57% against revenue growth of 48%. The fastest-growing cost line was Cost of revenue (+71%). Net earnings were $229.9M, up 39% year over year. The effective tax rate was 19.3%.
Operating cash flow was $240.9M (up 142% year over year), 105% of net earnings. Non-cash charges added back $4.5M of depreciation and amortization and $17.7M of share-based compensation. Capital expenditures of $4.2M left free cash flow of $236.7M.
Questions
What was Halozyme Therapeutics' revenue in the second quarter 2026?
Halozyme Therapeutics (HALO) reported revenue of $481M for the second quarter 2026 (Q2 2026), +48% from a year earlier and +28% from the quarter before.
Was Halozyme Therapeutics profitable in the second quarter 2026?
Operating profit was $288M (59.8% of revenue) and net earnings $230M.